Table 1.
1) interference with gp120 binding | |||
---|---|---|---|
Antibody | Binding site | Binding to CD4-gp120 complex | Characteristics |
OKT4a[76] | First CD4 domain | Does not occur due to epitope masking | Difficult to generate in vivo Immune suppressive |
2) interference with the sequence of conformational modifications subsequent to gp120 binding and permissive to coreceptor binding and membrane fusion | |||
Antibody | Binding site | Binding to CD4-gp120 complex | Characteristics |
Ibalizumab[46] | Second CD4 domain | Equivalent binding to free and complexed CD4 | Non immune suppressive |
DB-81[59,60] | Second CD4 domain | Increased binding to complexed CD4 | a) Non immune suppressive; b) Fine specificity shared by ESN individuals |